BIT:1LLY - Euronext Milan - US5324571083 - Common Stock - Currency: EUR
BIT:1LLY (3/7/2025, 7:00:00 PM)
802
-49.1 (-5.77%)
The current stock price of 1LLY.MI is 802 EUR. In the past month the price increased by 14.38%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY.DE | ELI LILLY & CO | 66.98 | 760.15B | ||
ZEG.DE | ASTRAZENECA PLC | 21.82 | 446.45B | ||
JNJ.DE | JOHNSON & JOHNSON | 16.81 | 372.31B | ||
1JNJ.MI | JOHNSON & JOHNSON | 16.61 | 367.98B | ||
NOV.DE | NOVO NORDISK A/S-B | 26.21 | 355.97B | ||
SNW.DE | SANOFI | 14.32 | 275.64B | ||
SAN.PA | SANOFI | 14.27 | 274.84B | ||
1SAN.MI | SANOFI | 14.19 | 273.18B | ||
6MK.DE | MERCK & CO. INC. | 12.64 | 224.82B | ||
1MRKX.MI | MERCK & CO. INC. | 12.47 | 221.79B | ||
PFE.DE | PFIZER INC | 8.69 | 140.81B | ||
1PFE.MI | PFIZER INC | 8.6 | 139.42B |
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 43,000 full-time employees. The firm discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies. The company is also developing oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).
ELI LILLY & CO
Lilly Corporate Ctr, Drop Code 1094
Indianapolis INDIANA US
Employees: 43000
Company Website: https://www.lilly.com/
Investor Relations: https://investor.lilly.com/
Phone: 13172762000
The current stock price of 1LLY.MI is 802 EUR. The price decreased by -5.77% in the last trading session.
The exchange symbol of ELI LILLY & CO is 1LLY and it is listed on the Euronext Milan exchange.
1LLY.MI stock is listed on the Euronext Milan exchange.
32 analysts have analysed 1LLY.MI and the average price target is 953.94 EUR. This implies a price increase of 18.95% is expected in the next year compared to the current price of 802. Check the ELI LILLY & CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ELI LILLY & CO (1LLY.MI) has a market capitalization of 760.43B EUR. This makes 1LLY.MI a Mega Cap stock.
ELI LILLY & CO (1LLY.MI) currently has 43000 employees.
ELI LILLY & CO (1LLY.MI) has a support level at 725.5 and a resistance level at 854.28. Check the full technical report for a detailed analysis of 1LLY.MI support and resistance levels.
The Revenue of ELI LILLY & CO (1LLY.MI) is expected to grow by 31.45% in the next year. Check the estimates tab for more information on the 1LLY.MI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ELI LILLY & CO (1LLY.MI) has a dividend yield of 0.66%. The yearly dividend amount is currently 4.55. Check the full fundamental report for a detailed analysis of 1LLY.MI dividend history, reliability and sustainability.
ELI LILLY & CO (1LLY.MI) will report earnings on 2025-05-01, before the market open.
The PE ratio for ELI LILLY & CO (1LLY.MI) is 67. This is based on the reported non-GAAP earnings per share of 11.97 and the current share price of 802 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 1LLY.MI.
ChartMill assigns a technical rating of 5 / 10 to 1LLY.MI.
ChartMill assigns a fundamental rating of 6 / 10 to 1LLY.MI. While 1LLY.MI belongs to the best of the industry regarding profitability, there are concerns on its financial health.
Over the last trailing twelve months 1LLY.MI reported a non-GAAP Earnings per Share(EPS) of 11.97. The EPS increased by 105.7% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 23.51% | ||
ROA | 13.45% | ||
ROE | 74.62% | ||
Debt/Equity | 2.01 |
ChartMill assigns a Buy % Consensus number of 83% to 1LLY.MI. The Buy consensus is the average rating of analysts ratings from 32 analysts.
For the next year, analysts expect an EPS growth of 79.4% and a revenue growth 31.45% for 1LLY.MI